Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia. Blood 2021 Nov 25;138(21):2138-2142
Date
09/10/2021Pubmed ID
34499715Pubmed Central ID
PMC8617436DOI
10.1182/blood.2021012392Scopus ID
2-s2.0-85119700502 (requires institutional sign-in at Scopus site) 9 CitationsAuthor List
Rossoff J, Baggott C, Prabhu S, Pacenta H, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras N, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LMAuthors
Amy Moskop MD Assistant Professor in the Pediatrics department at Medical College of WisconsinJulie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdolescentAdult
Antineoplastic Agents, Immunological
Child
Child, Preschool
Female
Humans
Immunotherapy, Adoptive
Infant
Male
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Receptors, Antigen, T-Cell
Retrospective Studies
Treatment Outcome
Young Adult